Changshan Pharmaceutical: The clinical trial application for Aibona peptide injection for weight loss indication has been approved.

Changshan Pharmaceutical announced that Changshan Pharmaceutical and its holding subsidiary Changshan Kaijiejian recently received the "Notice of Approval for Drug Clinical Trial" issued by the National Medical Products Administration. The clinical trial application for weight loss indication of Exenatide Injection has been approved. Exenatide is a long-acting glucagon-like peptide-1 receptor agonist, which stimulates insulin secretion and inhibits glucagon secretion by activating the GLP-1 receptor in a glucose concentration-dependent manner, while increasing glucose uptake in muscle and adipose tissue, inhibiting liver glucose production and exerting hypoglycemic effects. According to the requirements of drug registration laws and regulations, after obtaining the approval for clinical trial, the drug still needs to complete subsequent clinical trials and obtain approval from the National Medical Products Administration before it can be marketed. The acquisition of the approval for clinical trial will not have a significant impact on the company's recent performance. After obtaining the clinical trial permit, clinical trials need to be carried out. Clinical research is influenced by various uncertain factors, and there is a risk of results falling short of expectations or even failure of clinical research. Drug research and development has the characteristics of large investment, long cycle, high risk, etc. Drugs from clinical trials to production and marketing will be affected by various factors such as technology, approval, policy, etc., and there are uncertainties in the progress and results of clinical trials, as well as the future market competition situation of products.